StockNews.AI
PRAX
StockNews.AI
14 days

Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm

1. Praxis is under investigation for possible securities fraud. 2. Praxis shares fell by approximately 5.55% after announcing clinical trial results. 3. 36 of 61 patients reported adverse events in a key clinical trial. 4. 25% of trial participants discontinued participation, raising concerns. 5. The Portnoy Law Firm is seeking clients for potential class action.

3m saved
Insight
Article

FAQ

Why Bearish?

The investigation into securities fraud and the significant drop in share price indicates investor confidence is waning, reminiscent of similar cases that led to prolonged downtrends.

How important is it?

With ongoing litigation concerns and adverse trial results, there is a significant likelihood of impact on investor sentiment and stock value.

Why Short Term?

The immediate market reaction following the trial results and the initiation of an investigation suggests a short-term negative impact on PRAX's stock.

Related Companies

AMGNINCY
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Praxis Precision Medicines, Inc. (“Praxis” or “the Company”) (NASDAQ: PRAX) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Praxis investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: info@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses. On August 4, 2025, Praxis Precision Medicines, Inc. issued a press release announcing its financial results for the second quarter of 2025. In addition to its financial disclosures, the Company reported mid-stage clinical trial results for its anti-seizure medication, vormatrigine. Praxis disclosed that 36 of 61 patients experienced treatment-emergent adverse events, and nearly 25% of study participants discontinued participation. Following this announcement, Praxis’s stock price declined by $3.00 per share, or approximately 5.55%, closing at $51.09 per share on August 4, 2025. Please visit our website to review more information and submit your transaction information. The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes. Lesley F. Portnoy, Esq.Admitted CA, NY and TX Barslesley@portnoylaw.com310-692-8883www.portnoylaw.com Attorney Advertising

Related News